Beta-Thalassemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Beta-thalassemia (BT) is a genetic disorder characterized by a deficiency (Beta+) or absence (Beta0) of the beta-globin chains of hemoglobin (Hb). There are three main types of BT: BT-minor, BT-major, and BT-intermedia. BT-minor is the heterozygous form and is generally asymptomatic. At the same time, BT-major is the homozygous form that causes splenomegaly, microcytic and hypochromic anemia, and requires systematic transfusions to maintain Hb levels above 90-100 g/L. Long-term transfusion results in iron overload, which can cause significant morbidity and hamper the vital prognosis. BT-intermedia is less severe than BT-major and diagnosed later in life, and patients may or may not require occasional transfusions. Diagnosis of BT relies on analyzing Hb by electrophoresis or HPLC. Treatment options for BT include a combination of regular transfusions and iron chelation therapy, which has led to increased survival during the last 40 years. The prognosis depends on the severity of the condition, mainly if appropriate treatment is provided.

·       In the United States, β‐thalassemia, the reported incidence is 1 in 55,000 newborns.

Thelansis’s “Beta-Thalassemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Beta-Thalassemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Beta-Thalassemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Beta-Thalassemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Beta-Thalassemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033